MDxHealth SA
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MDXH in the last 7 days.
No SEC Form 4 filings for $MDXH in the last 30 days.
See all $MDXH insider activity →MDxHealth (MDXH) reported a 14% revenue increase to $51.1M for H1 2026, but net loss rose 18% to $19.2M due to higher operating expenses. Gross margin fell 4.2 points to 63.7%. The company faces going-concern doubts amid an accumulated deficit of $423.4M and expects continued losses.
Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).
MDxHealth reported Q2 2026 revenue of $27.2M, up 16% YoY, with gross profit at $17.9M. Operating loss increased to $5.1M, and net loss rose 36% to $9.5M. The company completed the wind-down of its Resolve UTI business. Management expressed confidence in meeting full-year revenue guidance of $110M-$115M and returning to adjusted EBITDA profitability by year-end, citing growth in its urology and prostate cancer diagnostics.
Recent MDXH coverage spans earnings, financial news and market movers.
The interim loss and cash burn raise short‑term risk, likely pressuring the stock lower.
Target reduction suggests bearish outlook.
Earnings beat revenue growth but widened losses; guidance suggests return to adjusted EBITDA profitability later this year.
New beneficial-ownership disclosure highlights concentrated holders, which can affect governance expectations but does not change operations or guidance.
The filing is a director-linked buy, but it is not a 10b5-1 plan and is unlikely to be a standalone catalyst for near-term fundamentals.
AlphAI scores every news story that mentions MDXH with an AI model for sentiment and relevance, and aggregates insider trades from MDxHealth SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
MDxHealth (MDXH) reported a 14% revenue increase to $51.1M for H1 2026, but net loss rose 18% to $19.2M due to higher operating expenses. Gross margin fell 4.2 points to 63.7%. The company faces going-concern doubts amid an accumulated deficit of $423.4M and expects continued losses.
2 min readAnalysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).
2 min readMDxHealth reported Q2 2026 revenue of $27.2M, up 16% YoY, with gross profit at $17.9M. Operating loss increased to $5.1M, and net loss rose 36% to $9.5M. The company completed the wind-down of its Resolve UTI business. Management expressed confidence in meeting full-year revenue guidance of $110M-$115M and returning to adjusted EBITDA profitability by year-end, citing growth in its urology and prostate cancer diagnostics.
2 min readMDxHealth SA (MDXH) shareholders Laurence W. Lytton and the Lytton-Kambara Foundation filed a Schedule 13G/A reporting beneficial ownership of 18,558,988 and 11,583,098 Ordinary Shares, or 19.5% and 12.1%, respectively, based on 95,417,382 shares outstanding as of Aug. 13, 2026.
2 min readMVM Partners, LLC purchased 2,202,643 indirectly-held shares of MDxHealth SA (MDXH) at $0.45 ($1.00M total) on 2026-08-13. Filed jointly with Bednarski Eric (Director).
1 min readmdxhealth reported Q2 tissue-based test volume rose 13% sequentially to 12,525 tests, aiding Q2 revenue of $27.2 million, up 16% year over year. Revenue for the first half of 2026 rose 14% to $51.1 million. Liquid Exo mdx volume was 13,578 tests, shifting mix and lowering gross margin to 65.7%. Operating loss widened to $5.1 million. On Aug. 11 it raised $20 million via share placement.
4 min readThe article highlights microcaps with near-term catalysts. Kartoon Studios (TOON) reported Q2 2026 revenue of about $5.8M and EPS about $0.38, including a $39.2M litigation settlement gain, and said an Amazon Prime Video deal will launch in Feb 2027. SurgePays (SURG) posted Q2 revenue up 40.7% to $16.2M and GAAP net income $1.29M. MDxHealth (MDXH) Q2 revenue rose 16% to $27.2M. IGC Pharma (IGC) expects Phase 2 topline results for IGC-AD1 in Q4 2026.
6 min readMDxHealth (NASDAQ: MDXH) reported Q2 2026 revenue of $27.2 million, up 16% year over year and 14% sequentially, and reaffirmed FY26 sales guidance of $110 million to $115 million. Gross profit rose to $17.9 million, but adjusted EBITDA turned negative at -$2.3 million. The company also received a Nasdaq minimum bid notice and raised $20 million via a registered direct placement.
6 min readMDxHealth SA (MDXH) reported Q2 2026 revenue up 16% year over year and its largest sequential growth, citing a renewed focus on core urology diagnostics after discontinuing the Resolve UTI business. The company reaffirmed 2026 revenue guidance of $110–$115 million and a return to adjusted EBITDA profitability.
1 min readMDxHealth SA (MDXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Mdxhealth Reports Second Quarter 2026 Financial Results Second quarter revenue growth of 16% to $27.2 million Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – August 13, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” o
2 min read
